Speaker
Description
Purpose: To evaluate whether the change of endothelial permeability during tumor progression can be assessed with the albumin-binding contrast medium gadofosveset in MRI.
Material and Methods: For the MRI protocol, anatomical T2, diffusion-weighted, T1/T2 map and dynamic contrast-enhanced sequences after the administration of gadofosveset trisodium were acquired. For the longitudinal study, BALB/c mice bearing a 4T1 (highly aggressive mammary carcinoma) or a 67NR (lowly malignant mammary carcinoma) were assessed by imaging, before the tumor was harvested for histology, immunofluorescence and mass spectrometry imaging.
Results: The MRI protocol has been established and 4T1 tumors have been evaluated longitudinally over nine days. Tumors show a rapid enhancement after i.v. injection of the contrast medium, the maximum is reached after about ten minutes.
Immunohistochemistry visualized a high proliferation rate, as demonstrated with positive staining for Ki67, as well as the expression of CD31 and VEGF.
Conclusion: The established MRI protocol can be used to evaluate the feasibility of measuring endothelial permeability of tumors with albumin-binding gadofosveset.
